TrianglePUBLICATIONS · 30523712
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2019 Feb 1
- First author
- Kater AP
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Kater AP
- type
- Author
- name
- Seymour JF
- type
- Author
- name
- Hillmen P
- type
- Author
- name
- Eichhorst B
- type
- Author
- name
- Langerak AW
- type
- Author
- name
- Owen C
- type
- Author
- name
- Verdugo M
- type
- Author
- name
- Wu J
- type
- Author
- name
- Punnoose EA
- type
- Author
- name
- Jiang Y
- type
- Author
- name
- Wang J
- type
- Author
- name
- Boyer M
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Kater AP
- type
- Author
- name
- Seymour JF
- type
- Author
- name
- Hillmen P
- type
- Author
- name
- Eichhorst B
- type
- Author
- name
- Langerak AW
- type
- Author
- name
- Owen C
- type
- Author
- name
- Verdugo M
- type
- Author
- name
- Wu J
- type
- Author
- name
- Punnoose EA
- type
- Author
- name
- Jiang Y
- type
- Author
- name
- Wang J
- type
- Author
- name
- Boyer M
- type
- Author
- bibliography ids
- nci-bib-3a13c9684cdd54b09037c0af
- book metadata
- content sha256
- 400b977d69d33b34837d479dc941db8107decca2aa21830591f7e7ad662d4f39
- document type
- citation
- dois
- 10.1200/JCO.18.01580
- electronic publication date
- display
- 2018 Dec 3
- precision
- day
- year
- 2018
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:30523712
- immutable id
- pubmed:30523712@400b977d69d33b34837d479dc941db8107decca2aa21830591f7e7ad662d4f39
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 4
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 269-277
- volume
- 37
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 30523712
- provenance
- batch id
- 438b2803888025c6cf56
- provider
- NCBI PubMed ESummary
- record sha256
- 480f30b9aaa83a411c95069f86fbfe75701ff95a8d87e9f5ed1e3b31021a62f7
- response sha256
- 0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
- retrieved at
- 2026-09-09T23:47:36.359220+00:00
- publication date
- display
- 2019 Feb 1
- precision
- day
- year
- 2019
- publication types
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Preserved source evidence · Not medical advice